Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy

gan Flinn, Ian W., Erter, Jack, Daniel, Davey B., Mace, Joseph R., Berdeja, Jesus G.
Cyhoeddwyd yn Oncologist (2019)

A Phase II Study of Two Dose Levels of Ofatumumab Induction followed by Maintenance Therapy in Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia (CLL)

gan Flinn, Ian W., Ruppert, Amy S., Harwin, William, Waterhouse, David, Papish, Steven, Jones, Jeffrey A, Hainsworth, John, Byrd, John C.
Cyhoeddwyd yn Am J Hematol (2016)

Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70

gan Kaplan, David, Sun, Zhuoxin, Tallman, Martin S., Flinn, Ian W., Xiao, Wenbin, Caimi, Paolo F., Kaye, Nicholas M., Lazarus, Hillard M.
Cyhoeddwyd yn Cytometry A (2014)

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-esca...

gan Stathis, Anastasios, Flinn, Ian W., Madan, Sumit, Maddocks, Kami, Freedman, Arnold, Weitman, Steven, Zucca, Emanuele, Munteanu, Mihaela C., Lia Palomba, M.
Cyhoeddwyd yn Invest New Drugs (2018)

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

gan Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Cyhoeddwyd yn Oncologist (2017)

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

gan Berdeja, Jesus G., Hart, Lowell L., Mace, Joseph R., Arrowsmith, Edward R., Essell, James H., Owera, Rami S., Hainsworth, John D., Flinn, Ian W.
Cyhoeddwyd yn Haematologica (2015)

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

gan Cheson, Bruce D., Byrd, John C., Rai, Kanti R., Kay, Neil E., O'Brien, Susan M., Flinn, Ian W., Wiestner, Adrian, Kipps, Thomas J.
Cyhoeddwyd 2012

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion coh...

gan Berdeja, Jesus G., Gregory, Tara K., Faber, Edward A., Hart, Lowell L., Mace, Joseph R., Arrowsmith, Edward R., Flinn, Ian W., Matous, Jeffrey V.
Cyhoeddwyd yn Am J Hematol (2021)

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

gan Woyach, Jennifer A., Awan, Farrukh, Flinn, Ian W., Berdeja, Jesus G., Wiley, Elizabeth, Mansoor, Sharmeen, Huang, Ying, Lozanski, Gerard, Foster, Paul A., Byrd, John C.
Cyhoeddwyd yn Blood (2014)

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

gan Byrd, John C., Kipps, Thomas J., Flinn, Ian W., Cooper, Maureen, Odenike, Olatoyosi, Bendiske, Jennifer, Rediske, John, Bilic, Sanela, Dey, Jyotirmoy, Baeck, Johan, O'Brien, Susan
Cyhoeddwyd 2012

Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study

gan Flinn, Ian W., Patel, Manish, Oki, Yasuhiro, Horwitz, Steven, Foss, Francine F., Allen, Kerstin, Douglas, Mark, Stern, Howard, Sweeney, Jennifer, Kharidia, Jahnavi, Kelly, Patrick, Kelly, Virginia M., Kahl, Brad
Cyhoeddwyd yn Am J Hematol (2018)

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

gan Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Flinn, Ian W., Burger, Jan A., Tran, Anh, Clow, Fong, James, Danelle F., Graef, Thorsten, Friedberg, Jonathan W., Rai, Kanti, O’Brien, Susan
Cyhoeddwyd yn Blood (2015)

A Phase I/II Dose Escalation Study of Apolizumab (Hu1D10) Using a Stepped Up Dosing Schedule in Patients with Chronic Lymphocytic Leukemia (CLL) and Acute Leukemia

gan Lin, Thomas S., Stock, Wendy, Xu, Huiping, Phelps, Mitch A., Lucas, Margaret S., Guster, Sara K., Briggs, Bruce R., Cheney, Carolyn, Porcu, Pierluigi, Flinn, Ian W., Grever, Michael R., Dalton, James T., Byrd, John C.
Cyhoeddwyd yn Leuk Lymphoma (2009)

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Fo...

gan Flinn, Ian W., van der Jagt, Richard, Kahl, Brad, Wood, Peter, Hawkins, Tim, MacDonald, David, Simpson, David, Kolibaba, Kathryn, Issa, Samar, Chang, Julie, Trotman, Judith, Hallman, Doreen, Chen, Ling, Burke, John M.
Cyhoeddwyd yn J Clin Oncol (2019)

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in P...

gan Wahl, Richard L., Frey, Eric C., Jacene, Heather A., Kahl, Brad S., Piantadosi, Steven, Bianco, Jesus A., Hammes, Richard J., Jung, Miah, Kasecamp, Wayne, He, Bin, Sgouros, George, Flinn, Ian W., Swinnen, Lode J.
Cyhoeddwyd yn Cancers (Basel) (2021)

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

gan Byrd, John C., Kipps, Thomas J., Flinn, Ian W., Castro, Januaro, Lin, Thomas S., Wierda, William, Heerema, Nyla, Woodworth, James, Hughes, Steve, Tangri, Shabnam, Harris, Sarah, Wynne, Dee, Molina, Arturo, Leigh, Bryan, O'Brien, Susan
Cyhoeddwyd 2010

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

gan Sonnichsen, Daryl, Dorer, David J., Cortes, Jorge, Talpaz, Moshe, Deininger, Michael W., Shah, Neil P., Kantarjian, Hagop M., Bixby, Dale, Mauro, Michael J., Flinn, Ian W., Litwin, Jeffrey, Turner, Christopher D., Haluska, Frank G.
Cyhoeddwyd 2013

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

gan Shah, Neil P., Talpaz, Moshe, Deininger, Michael W. N., Mauro, Michael J., Flinn, Ian W., Bixby, Dale, Lustgarten, Stephanie, Gozgit, Joseph M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Kantarjian, Hagop, Cortes, Jorge E.
Cyhoeddwyd 2013

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

gan Byrd, John C., Smith, Stephen, Wagner-Johnston, Nina, Sharman, Jeff, Chen, Andy I., Advani, Ranjana, Augustson, Bradley, Marlton, Paula, Renee Commerford, S., Okrah, Kwame, Liu, Lichuan, Murray, Elaine, Penuel, Elicia, Ward, Ashley F., Flinn, Ian W.
Cyhoeddwyd yn Oncotarget (2018)

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

gan Byrd, John C., Smith, Stephen, Wagner-Johnston, Nina, Sharman, Jeff, Chen, Andy I., Advani, Ranjana, Augustson, Bradley, Marlton, Paula, Commerford, S. Renee, Okrah, Kwame, Liu, Lichuan, Murray, Elaine, Penuel, Elicia, Ward, Ashley F., Flinn, Ian W.
Cyhoeddwyd yn Oncotarget (2019)